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DObjective: One of the challenges that exists when discussing the Cox maze procedure for atrial fibrillation (AF)
with patients is predicting the success for a given patient. The purpose of the present study was to develop a
scoring system using well-established clinical factors to predict the probability of sinus rhythm (SR) after sur-
gery.
Methods: The data from patients 1 and 2 years postoperatively were analyzed using logistic regression to predict
SR, including the most accepted variables associated with failure (age, left atrium size, AF duration, AF type).
Regression models were applied using hypothetical patients to examine the predicted probability of SR.
Results: The predictors of 1-year SR were a shorter AF duration and greater surgeon experience performing
surgical ablation. The predictors at 2 years were a shorter AF duration and smaller left atrium. The 1-year pre-
diction model applied to hypothetical data found a 1-cm increase in left atrial size associated with a 0.4% reduc-
tion in SR probability, a 5-year increase in AF duration associated with a 0.8% reduction, and a reduction by 50
cases of surgeon experience associated with a 1.0% reduction. The 2-year model found a 1-cm increase in left
atrial size associated with a 1.0% reduction in SR probability, a 5-year increase in AF duration associated with a
0.8% reduction, and a reduction by 50 cases of experience associated with a 0.2% reduction.
Conclusions: Our findings are the first step in establishing a risk scoring system to better predict the outcomes
after surgical ablation for AF and improve the ability to discuss the risk and benefits with patients. (J Thorac
Cardiovasc Surg 2014;148:881-7)ASince its introduction and refinement during recent decades,
the Cox maze procedure for surgical ablation of atrial
fibrillation (AF) has become the reference standard for the
surgical treatment of AF.1,2 The overall freedom from
symptomatic AF and restoration of sinus rhythm (SR)
after the Cox maze procedure has been high in reported
studies.3-5
Several well-established clinical variables have been
associated with failure of the Cox maze procedure.6-8
However, despite the significant progress associated with
advanced surgical ablation technology and well-
established guidelines, the field still lacks reliable risk
prediction models to improve patient selection for surgical
ablation and help predict the efficacy of the procedure.8,9
The most acceptable variables associated with surgical
ablation for AF outcome have been age, left atrial (LA)
size, type and duration of AF, and the number of
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The Journal of Thoracic and CaIn the present study, we examined data that had been
prospectively collected from patients who had undergone
the Cox maze III or IV procedure for AF ablation concom-
itantly with other cardiac procedures through a mid-
sternotomy. The study purpose was to develop a risk scoring
platform to predict the probability of SR at 1 and 2 years
after the Cox maze procedure that could be applied in an
informative manner to a larger group of patients.
METHODS
The full concomitant Cox maze III or IV was performed in 501 consec-
utive patients by way of a median sternotomy at a single center from
January 2005 to October 2013. Our institutional review board approved
the present study (approval nos. 06.022 and 12.055). Data regarding clin-
ical events, medication, and rhythm status were collected prospectively
before and after surgery, and follow-up data were collected at 3, 6, 9, 12,
18, and 24 months postoperatively and annually thereafter. Rhythm status
was verified by electrocardiography and 24-hour Holter monitoring at each
follow-up point for all patients. The Heart Rhythm Society (HRS) defini-
tion of failure (all documented atrial arrhythmias lasting>30 seconds)
was used to determine the return to SR.14 In the present study, the endpoint
of rhythm status was capturedwithout consideration of antiarrhythmic drug
treatment. The data collected using our local surgical ablation registry were
merged with data from our local Society of Thoracic Surgeons database. At
1 year postoperatively, 303 patients were available for the analyses with
complete follow-up data, and at 2 years, 195 patients were available for
the analyses.
Operative Approach
The Cox maze procedure III or IV was performed by multiple surgeons,
as previously described.15,16 The LA appendage was managed at the
surgeon’s discretion in all patients using either excision or exclusion
(surgically, AtriClip, or multiple endoloops). Appropriate control of therdiovascular Surgery c Volume 148, Number 3 881
Abbreviations and Acronyms
AF ¼ atrial fibrillation
AUC ¼ area under the curve
CI ¼ confidence interval
HRS ¼ Heart Rhythm Society
LA ¼ left atrial
OR ¼ odds ratio
SR ¼ sinus rhythm
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DLA appendage was confirmed by echocardiography in all patients. The
ablative energy source used for the Cox maze procedure was
cryothermia alone (Medtronic, Minneapolis, Minn) in 56% of the
patients and a combination of bipolar radiofrequency and cryothermia
(AtriCure, Cincinnati, Ohio) in 44% of the patients.
Statistical Analysis
All analyses were conducted using the Statistical Package for the Social
Sciences, version 17.0 (SPSS Inc, Chicago, Ill), and 2-tailed P values were
used. Continuous data are presented as the mean  standard deviation or
median and interquartile range, and categorical data are presented as fre-
quencies and percentages, unless otherwise noted. Group comparisons
for categorical variables were conducted with the chi-square test or Fisher’s
exact test, and comparisons for continuous variables were conducted using
Student’s t test or the Mann-Whitney U test based on test assumption re-
quirements. Multivariate logistic regression was used to determine the pre-
diction model for SR at 1 and 2 years postoperatively and included the
following factors determined a priori: age, gender, preoperative LA size
(cm), duration of AF before surgery, AF type, number of concomitant sur-
gical procedures, and surgeon experience in surgical ablation. The number
of concomitant surgical procedures was operationally defined as the total
additive number of any surgical procedures performed concomitantly
with the Cox maze procedure. Surgeon experience (continuous measure)
was defined as the number of surgical ablation procedures the patient’s sur-
geon had performed before their surgery and then scaled by 10 for use in the
multivariate model. After obtaining the coefficients for each logistic regres-
sion model, internal validation of the prediction models was conducted us-
ing ordinary nonparametric bootstrapping with 999 bootstrap samples and
bias-corrected, accelerated 95% confidence intervals (CIs). Receiver oper-
ating characteristic curves were constructed for both 1- and 2-year models,
and bootstrapping with 999 samples was performed to evaluate the reli-
ability of the area under the curve (AUC) for each model. In addition, hy-
pothetical patients were evaluated using the predictionmodels to determine
the effect that changes in the predictor factors would have on the probabil-
ity for SR.
The prediction models were then applied to all patients with complete
predictor variable data (n ¼ 439; LA size missing, n ¼ 32; AF duration
missing, n ¼ 30), even those without observed rhythm status information,
to determine the predicted probability of SR rhythm at each follow-up
point. Patients at the high and low end of individual predictor variables
from the model were examined with respect to predicted probability of
SR from the 1- and 2-year models. For continuous factors (ie, age, LA
size, duration of AF), tertiles were created, and the lowest and highest ter-
tile groups were compared for the predicted probability of SR.RESULTS
The clinical characteristics of the patients available for
the analyses at 1 and 2 years after concomitant Cox maze
surgery are listed in Table 1. The mean patient age was 66882 The Journal of Thoracic and Cardiovascular Surgyears, and approximately 60% of patients were male at
both measurement points. The surgeon experience for these
patients ranged from 1 case to>250 cases. The preoperative
and surgical factors remained similar in the 1- and 2-year
samples, given the overlap in patients between the 2. At 1
year, 92% of the patients (280 of 303) were in SR, and
90% were in SR and did not require class I or III antiar-
rhythmic medication. By 2 years, 90% of patients (175 of
195) were in SR, and 90% were in sinus rhythm and did
not require antiarrhythmic medication.
Multivariate Regression Analyses
The significant independent predictors of 1-year SR were
a shorter duration of AF in years (odds ratio [OR], 0.91;
95% CI, 0.84-0.98; P ¼ .02) and surgeon experience
(OR, 1.12; 95% CI, 1.06-1.19; P<.001; Table 2). The sig-
nificant predictors of 2-year SR were a shorter duration of
AF in years (OR, 0.88; 95% CI, 0.79-0.99; P ¼ .03) and
smaller LA size (OR, 0.49; 95% CI, 0.26-0.90; P ¼ .02).
Internal validation of both logistic regression models was
conducted using bootstrapping with 999 samples; the re-
sults are presented in Table 3. Almost all variables included
in the model demonstrated robust results, with small 95%
CIs around the original coefficients. The 2 dummy-coded
variables that constituted the AF type appeared to be less
reliable, with wider 95% CIs around the original coeffi-
cients. Evaluation of the 1-year prediction model with
receiver operating characteristic curve analysis found an
AUC of 0.858; however, bootstrapping revealed an AUC
of 0.817 (95% CI, 0.705-0.913). For the 2-year prediction
model, the receiver operating characteristic curve analysis
found an AUC of 0.859, and bootstrapping revealed an
AUC of 0.844 (95% CI, 0.761-0.918).
Application of Prediction Models
These models can be applied to any patients with com-
plete predictor variable data using 3 steps. First, one enters
the patient’s information into the appropriate boxes in
Table 4 and multiplies each value by the weight for that
variable. Second, one sums all weighted values with the
constant in the appropriate column, which will provide
the logit(P). Third, one enters the logit(P) value into the
following equation to determine the predicted probability:
P ¼ 1/[1 þ elogit(P)]. Importantly, application of the
1-year prediction model to a hypothetical typical patient
(65-year-old, male patient with an LA size of 5.0 cm and
3-year duration of persistent AF who underwent 1 concom-
itant procedure by a surgeon with 150 cases of experience)
found a 98.6% probability of SR at 1 year and a 99.1%
probability of SR at 2 years. Keeping all other parameters
constant for the hypothetical patient, the 1-year prediction
model found that a 1-cm increase in LA size was associated
with a 0.4% reduction, a 5-year increase in AF duration was
associated with a 0.8% reduction, changing the AF type toery c September 2014
TABLE 1. Patient characteristics for those with rhythm status at 1 and
2 years postoperatively
Characteristic
Patients at
1 y (n ¼ 303)
Patients at
2 y (n ¼ 195)
Age (y) 66.1  11.7 65.8  11.7
Female gender 128 (42) 82 (42)
Ejection fraction (%) 54.7  11.7 54.9  11.6
Congestive heart failure 134 (44) 87 (45)
Diabetes 41 (14) 30 (15)
Chronic pulmonary disease 42 (14) 24 (12)
Preoperative creatinine level 1 (0.8-1.1) 1 (0.8-1.2)
Peripheral vascular disease 23 (8) 16 (8)
Cerebrovascular disease 33 (11) 20 (10)
Previous CVA 21 (7) 13 (7)
Hypertension 200 (66) 135 (69)
Logistic EuroSCORE I (%) 8.1  8.4 7.8  7.5
Left atrial size (cm) 5.1  1.0 5.2  0.9
AF type
Longstanding, persistent 147 (48.5) 104 (53)
Persistent 121 (40) 74 (38)
Paroxysmal 35 (11.5) 17 (9)
AF duration (mo) 39.8  60.1 37.4  50.2
Previous cardioversion 101 (33) 66 (34)
Previous ablation 33 (11) 21 (11)
Concomitant CABG* 98 (32) 66 (34)
Concomitant valve surgery* 257 (85) 165 (85)
Cardiopulmonary bypass time (min) 178.4  50.7 180.7  51.2
Crossclamp time (min) 120.4  38.9 123.5  37.5
Data presented as n (%), mean standard deviation, or median (interquartile range).
CVA, Cerebrovascular accident; AF, atrial fibrillation; CABG, coronary artery bypass
grafting; EuroSCORE, European System for Cardiac Operative Risk Evaluation.
*Categories not mutually exclusive.
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reduction, and a decrease of 50 cases in surgeon experience
was associated with a 1.0% reduction in the predicted prob-
ability of SR at 1 year. Keeping the other parametersTABLE 2. Results of multivariate logistic regression models
predicting sinus rhythm at 1 and 2 years after Cox maze procedure
Variable
1-y SR* 2-y SRy
B OR P value B OR P value
Age 0.005 1.01 .83 0.021 0.98 .41
Female gender 0.013 0.99 .98 0.348 1.42 .55
LA size 0.275 0.76 .25 0.723 0.49 .02
AF duration (y) 0.093 0.91 .02 0.125 0.88 .03
AF type
Persistent vs paroxysmal 0.260 0.77 .84 1.664 5.28 .26
Longstanding vs
paroxysmal
1.336 0.26 .24 0.506 0.60 .66
Surgeon experience 0.114 1.12 <.001 0.038 1.04 .09
Total concomitant
procedures
0.648 0.52 .08 0.607 0.55 .10
Constant 4.814 8.407
SR, Sinus rhythm; B, regression coefficient; OR, odds ratio; LA, left atrial; AF, atrial
fibrillation. *Omnibus test, chi-square¼ 45.3, P<.001; Hosmer-Lemeshow test, chi-
square ¼ 7.8, P ¼ .45. yOmnibus test, chi-square ¼ 32.3, P < .001; Hosmer-
Lemeshow test, Chi-Square ¼ 6.1, P ¼ .63.
The Journal of Thoracic and Caconstant, the 2-year prediction model found that a 1-cm
increase in LA size was associated with a 1.0% reduction,
a 5-year increase in AF duration was associated with a 0.8%
reduction, a change to longstanding persistent AF was asso-
ciated with a 6.6% reduction, and a reduction of 50 cases of
surgeon experiencewas associated with a 0.2% reduction in
the predicted probability of SR at 2 years.
Applying the prediction model to an older patient
(78-year-old man) with clinical characteristics similar to
the typical patient described in the previous paragraph re-
sulted in a 98.7% predicted probability of SR at 1 year
and 98.8% predicted probability of SR at 2 years. Keeping
all other factors constant, the effect of changing to a less
experienced surgeon (10 total cases of experience) changed
the results for this older patient to a 94.0% probability of
SR at 1 year and 98.0% probability of SR at 2 years
postoperatively.
After determining which patients were in the highest and
lowest tertiles of continuous variables for all patients with
complete predictor variable data (n ¼ 439), the analyses
indicated that the predicted probability of SR was signifi-
cantly lower for those with the longest AF duration (>3.2
years) than for those with the shortest AF duration (<0.37
years) at the 1- and 2-year points (89% vs 97%,
P < .001; and 81% vs 98%, P < .001, respectively;
Figure 1). For the LA size tertile comparisons, the predicted
probability of SR was significantly lower for patients with a
larger LA size (>5.5 cm) than for those with a smaller LA
size (<4.6 cm) at 2 years (84% vs 96%, P<.001) but not
at 1 year (92% vs 94%, P ¼ .08; Figure 2). In the oldest
age tertile group (>72 years), the predicted probability of
SR was lower than in the youngest age tertile group (<63
years) at 2 years (89% vs 94%, P< .001) but not at 1
year (92% vs 94%, P ¼ .27). The predicted probability
of SR was greater for surgeons in the highest tertile of expe-
rience (>301 cases) than for surgeons in the lowest tertile of
experience (<62 cases) at both 1 and 2 years after surgery
(99.6% vs 84%, P< .001 and 94% vs 88%, P< .001,
respectively). No differences were seen by gender for the
1- or 2-year predicted probability of SR.
DISCUSSION
In the present large cohort study, we identified significant
predictive models for the success of the Cox maze proce-
dure performed concomitantly with other cardiac proce-
dures. In these models, the significant predictors of SR
were a shorter duration of AF, a smaller LA size, and greater
surgeon experience in performing surgical ablation. Once
these prediction models for SR at 1 and 2 years after the
Cox maze procedure undergo additional testing and valida-
tion, the prediction method can be applied to any patient
with the necessary data points. These findings are the first
step in establishing a risk scoring system that will allow bet-
ter prediction of the rhythm outcome after surgical ablationrdiovascular Surgery c Volume 148, Number 3 883
TABLE 3. Internal validation of prediction models using nonparametric bootstrap technique
Variable
1-y SR 2-y SR
Original Bias SE 95% BCa CI Original Bias SE 95% BCa CI
Age 0.005 0.003 0.035 0.07 to 0.06 0.021 0.010 0.041 0.11 to 0.04
Female gender 0.013 0.020 0.607 1.27 to 1.04 0.348 0.214 0.924 1.74 to 1.46
LA size 0.275 0.027 0.337 0.91 to 0.48 0.723 0.116 0.507 1.54 to 0.41
AF duration 0.093 0.013 0.048 0.17 to 0.02 0.125 0.030 0.084 0.27 to 0.03
AF type
Persistent vs paroxysmal 0.260 5.399 8.010 16.10 to 18.11 1.664 0.030 11.016 15.40 to 19.27
LS persistent vs paroxysmal 1.336 5.765 7.718 17.17 to 1.02 0.506 5.610 8.235 18.34 to 2.52
Surgeon experience 0.114 0.021 0.059 0.04 to 0.19 0.038 0.006 0.032 0.02 to 0.10
Concomitant procedures 0.648 0.053 0.487 1.61 to 0.28 0.607 0.022 0.529 1.64 to 0.49
Constant 4.814 6.290 8.394 3.59 to 19.77 8.407 7.169 10.130 1.29 to 26.51
SR, Sinus rhythm; SE, standard error; BCa, adjusted bootstrap confidence interval; CI, confidence interval; LA, left atrial; AF, atrial fibrillation; LS, longstanding.
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and benefits with their patients.
In recent years, multiple risk prediction models have been
developed for patients undergoing cardiac surgery. These
models have focused mainly on the operative and peri-
operative outcomes and the associated risk of morbidity
and mortality after the surgical intervention.17-19 The
availability of such risk models improved the ability of
surgeons to communicate with patients and referring
physicians about the predicted risk. Such risk models are
also excellent tools for understanding the cost effectiveness
across different approaches and new technologies, with the
best example being the large US transcatheter valve studies.
The field of surgical ablation of AF using different surgi-
cal ablation devices is relatively new and faces significant
challenges. It is well established that a lack of standardiza-
tion exists with surgical ablation for AF in terms of the
decision making to perform surgical ablation and incorrect
perceptions regarding the risk and effectiveness of the pro-
cedure.20,21 Just as important, different surgeons will apply
different lesion sets and use different ablative devices in
different situations, sometimes with inferior outcomes.22-24TABLE 4. Sinus rhythm prediction model calculator
Variable
1-y model 2-y model
Coefficient
(B) 3 value
Coefficient
(B) 3 value
Age (y) 0.005 3 ____ 0.021 3 ____
Gender* 0.013 3 ____ 0.348 3 ____
LA size (cm) 0.275 3 ____ 0.723 3 ____
AF duration (y) 0.093 3 ____ 0.125 3 ____
AF type Ay 0.260 3 ____ 1.664 3 ____
AF type Bz 1.336 3 ____ 0.506 3 ____
Surgeon experiencex 0.114 3 ____ 0.038 3 ____
Concomitant proceduresjj 0.648 3 ____ 0.607 3 ____
Constant 4.814 8.407
*Male, enter 0; female, enter 1. yParoxysmal, enter 0; persistent, enter 1; longstanding
persistent, enter 0. zParoxysmal, enter 0; persistent, enter 0; longstanding persistent,
enter 1. xEnter total number of surgical ablation cases previously performed by sur-
geon divided by 10. jjEnter total number of concomitant procedures, not including
Cox maze procedure.
884 The Journal of Thoracic and Cardiovascular SurgThe Cox maze procedure has been considered the stan-
dard for surgical ablation for AF.3 Since the first cut and
sew procedure performed>25 years ago, a major shift in
the surgical technique to apply the lesions has been made,
and it is now being applied almost solely using surgical
ablative tools, with rare exceptions. When done appropri-
ately, the transition to ablative tools has been associated
with success rates similar to those reported for the cut and
sew procedure.25
The recent American Association for Thoracic Surgery
survey revealed that a real gap exists between surgeons’
perception and the real world data related to surgical abla-
tion for AF.21 Despite established, evidence-based guide-
lines and consensus statements, surgeons have been
reluctant to perform surgical ablation concomitantly with
other cardiac surgical procedures, mainly secondary to an
incorrect perception of increased operative risk and lack
of efficiency.9,14,20 Multiple recent publications have
demonstrated the safety and improved long-term survival
associated with surgical ablation for AF.26-28 Therefore,FIGURE 1. Predicted probability of sinus rhythm at 1 and 2 years strati-
fied by duration of atrial fibrillation. AF, Atrial fibrillation.
ery c September 2014
FIGURE 2. Predicted probability of sinus rhythm at 1 and 2 years strati-
fied by left atrial size.
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the essential nature of surgical ablation to improve
delivery of care.
The prediction model we have presented is the first step
in establishing a more universal model. To move forward
from this first step, these rhythm prediction models will
need to undergo external validation with larger patient co-
horts from multiple centers. We were able to apply internal
validation techniques to understand how likely these
models will be replicable in future studies and at other cen-
ters. Bootstrapping techniques were applied and demon-
strated that the coefficients obtained from these prediction
models were quite robust. The type of AF was the 1 factor
that the bootstrap results indicated might have limited
repeatability in future work. Removal of the AF type from
the models did not change which factors were significant
predictors of SR. However, because of the clinical impor-
tance surrounding the type of AF, this variable was kept
as a factor in these models despite some statistical limita-
tions (ie, categorical variable, collinearity). Also, other
studies have found a significant effect of the AF type on out-
comes, and the choice of factors for the model had focused
on including the most accepted predictors for SR after sur-
gical ablation.11,29 In the real-world clinical setting where
these prediction models could be used, the type of AF is
an important clinical characteristic that can play a substan-
tial role in surgical decision making.Study Limitations
The main limitations of the present study involved the
statistical shortcomings associated with attempting to pre-
dict outcomes in such a way that incorporates both previous
research evidence and clinical considerations. As previ-
ously discussed, the inclusion of the AF type in theThe Journal of Thoracic and Caprediction models introduced ambiguity regarding the
reproducibility of the effect of the AF type in future predic-
tion models. Although overlap existed between factors such
as the AF duration and the AF type, the collinearity in these
models was not largely affected by inclusion of the AF type.
Another potential limitation of this model was that any
type of concomitant procedure was counted equally in the
analyses and therefore considered equally important in the
prediction models. For example, it might be that the effect
of a valve procedure differs from that of the addition of cor-
onary artery bypass grafting. However, to answer this ques-
tion, a much larger group of patients would be required.
Also, we chose to use the HRS definition of success,
regardless of antiarrhythmic medication status. The main
reason for this decision was the variability in antiarrhythmic
medication management. Our center has strongly recom-
mended that any patient who returns to SR, as verified by
24-hour Holter monitoring, should have their antiar-
rhythmic medications stopped by 6 months postoperatively.
However, at any given point after Cox maze surgery, it is
possible that patients truly in SR will continue to take anti-
arrhythmic medication despite their eligibility to stop the
medication. Therefore, we believed that the prediction of
a return to SR regardless of medication status represented
a less biased outcome measure.CONCLUSIONS
In the present study, we were able to establish what
should be considered the first step in improving our ability
to predict the rhythm outcome for the first 2 years after the
Cox maze procedure when performed concomitantly
through a median sternotomy. Applying this risk scoring
system to potential patients could result in a much improved
preoperative assessment and discussion related to the
procedure.
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Dr Richard Lee (St Louis, Mo). I have no disclosures. Dr Ad,
this is an important contribution to the field. I have 2 questions that
I will ask 1 at a time.
First, the freedom from AF that you reported was an impressive
95%, which has been duplicated in some other single institution
series. However, in the Concomitant Utilization of Radio Fre-
quency Energy for Atrial Fibrillation trial and ABLATE-AF trial,
the freedom from atrial fibrillation was 67% and 84%, respec-
tively, using the same lesion set as in your series at multiple centers
and with multiple surgeons. How do you account for the superior-
ity of your results and does this limit the generalizability of your
prediction model to other centers?
Dr Ad.Well, Rick, thank you. There are many ways to answer
this question. One of the only smart decisions I made regarding
the surgical treatment of AF was basically to take what I learned
in the past very seriously; I never changed it. Dr Jim Cox pre-
sented his concept>25 years ago, and I actually never moved
away from it.
I believe that the only difference between our group and others
is that we all perform the correct Maze lesion set using only tools
with proven transmurality; these are not only my own results. I
think if you do this, your success rate is going to be high.
Dr Lee. Second, in your report, you were kind enough to cite
one of my studies that showed a survival advantage for patients
surgically treated for AF. However, in that population, only those
patients whowere free from both AF and antiarrhythmic therapy at
1 year had improved survival, similar to the implications of the
multivariable analysis of the Atrial Fibrillation Follow-up Investi-
gation of Rhythm Management trial.
Please clarify why you did not use freedom from AF and anti-
arrhythmic agents as a primary endpoint and what needs to
be done to establish a prediction model for this important
variable?
Dr Ad.Well, that is an interesting question. Again, this is a first
step, and I think it is an important step, where we can sit and talk
with the patient and say, you know, this is the prediction of you be-
ing in SR.Whether SR without and with medication is the key, this
is still an open question, and, despite the guidelines, some of us
strongly disagree with this type of definition. However, being
clearer, the model is still as accurate when you take the medication
variable out, we just did not believe it was important to include
here to avoid confusion. I think in the future when we have more
collaboration and more patients, we will be able to also predict
freedom from cardioversion and freedom from antiarrhythmic
drugs.ery c September 2014
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DMind you, we were persistent in the adherence to the HRS
guidelines, such that any ablation was considered a failure.
Dr Vinay Badhwar (Pittsburgh, Pa). Niv, another wonderful
contribution, and I think what is extremely important is that all
our current scoring systems of the quality of cardiac surgery are
currently focused on major morbidity and mortality outcomes,
and this is one of the first that will be focusing on a no mortality
and no morbidity procedural efficacy outcome.
I know from your past work that your lesion set has been consis-
tent, as has been its energy source. As a part of your predictive
model, just for clarification of us all, was this consistent
throughout all patients and all surgeons performing the same
lesion set with the same ‘‘tool,’’ as you called it?
Dr Ad. I am not operating all the time, but the group, in general,
I think is fairly educated about the lesion sets and how to apply
them, and I believe that this is the key. Also, the energy sources be-
ing used were either cryothermia alone or a combination of bipolar
radiofrequency and cryothermia, which previous publications,
ours and others, showed no difference between them.
Dr Badhwar. On the basis of that answer, perhaps it would be
wise to include the energy source and precise lesion set adherence
before external validation. Do you think this would be a factor in
the development of a scoring system?
Dr Ad. I think that it might be a good idea. I question whether it
is going to add anything, because I predict that, at least in our
model, it will not show any significance at 1 or 2 years whether
you use bipolar and cryothermia or cryothermia alone, and Ralph
is here and can comment on that. I think it is an excellent question.
I just do not believe that, at least in our center, it will show any
difference.
As for a lesion set, this is specifically a Cox maze III or IV, it
depends on how you want to call it, lesion set in all patients, and
that is crucial. I can go back and look, because, as you know, in
our database it has been entered after every case whether there
were deviations from the Cox maze procedure perceived by the
surgeon, and, again, if so, it occurred in very few patients.
Dr A. Peter Kappetein (Rotterdam, The Netherlands). It is
great, as Dr Badhwar pointed out, that you have developed an ef-
ficacy model instead of just a safety model. The AUC of 0.85 is
impressive and very difficult to achieve in any other prediction
model. You only had 525 patients to develop this model, and
your success rate was pretty high for achieving SR.
So how many endpoints did you have? In other words, how
many patients had AF during follow-up? Because these are the
ones for which you want to try to find the predictive factors.
That is a relatively small proportion.
In your abstract, you stated that a 1-cm increase in LA size re-
sulted in a 2.3% reduction in the success rate. That means that if
you have a success rate of 98%, it will decrease to 95.7%. How
can it be so accurate, and do you assume that all variables have
a linear relationship with the outcome? Because I can also imagine
that if the LA size is greater than a certain threshold, treatment will
not be so successful.
Dr Ad. I think that it is something we were surprised at. This
obviously I consider one of our most important projects ever. I
was fairly surprised, and we did check ourselves again and again
and again, and these are indeed the data, and whoever knows usThe Journal of Thoracic and Caknows that this is really something we take a lot of pride in, our
reliability in reporting results.
The LA size might be a little different in the prediction for fail-
ure compared with other centers, because more experienced sur-
geons were managing a larger atrial size. Also, we published a
couple of months ago that 2 sizes are crucial in which we should
pay attention for success, whether with or without medication,
5.5 cm and 7.5 cm. However, even if you treat patients with
a>10-cm left atrium, the success rate without medication at 2
years was>50%, but there are not many.
Dr Kappetein. So you assume still that you can use it as a
continuous variable instead of as a categorical variable?
Dr Ad. Yes.
DrKappetein.Howmany patients actually did not achieve SR?
In how many patients was treatment not successful?
Dr Ad. I do not remember off the top of my head, but, again, we
classified failures in a few categories that can correlate with
burden: 30 seconds to 5 minutes, 5 minutes to 1 hour,>1 hour,
and continuous. But I do not remember it off the top of my head.
Dr Kappetein. Because that is a very important figure.
Dr Ad. Good point.
Dr Sary F. Aranki (Boston, Mass). I have a question regarding
anticoagulation. How do you use your prediction model in manag-
ing anticoagulation in those patients and does the size of the left
atrium have any effect on your management decision?
Dr Ad. First, the prediction model is not designed to answer
whether the patient will require anticoagulation. What we do prac-
tically for anticoagulation is basically 3 months of postoperative
antiarrhythmic drugs and anticoagulation, then we stop the antiar-
rhythmic drugs, and we monitor the patient—long-term moni-
toring, anywhere from 4.5 months to 6 months. When we see
that they are basically not in AF based on this type of assessment
and the echocardiogram shows that no smoke is present in the
atrium and the LA appendage has been controlled, the recommen-
dation to stop anticoagulation applies.
If smoke is present in the left atrium or the LA appendage is not
well controlled and the patient has higher CHADS scores, we have
some discussions around all of it. Our rate of stopping anticoagu-
lation has been fairly high. One caveat is that in many cases it will
be the decision of the cardiologist, and, despite our recommenda-
tion, the patient will continue with anticoagulation medication.
However, theoretically, if you remove all the patients who do not
require anticoagulation due to AF or other reasons, such as a
mechanical valve or deep venous thrombosis, you can basically
eliminate warfarin in>85% of the patients after 6 months.
Dr Harold L. Lazar (Boston, Mass). I just have 1 final ques-
tion. Using your scoring system, are there any patients for whom
you would not perform a concomitant maze procedure because
you think that it just would not work?
Dr Ad. No, for myself; however, in the group, I think it varies.
We have shown in the past, in work that was published in the
Annals, that attrition occurs in the implementation of the Cox
maze procedure for patients with more risk factors and, especially,
with a larger left atrium and long AF duration. However, person-
ally, I think you can achieve much greater than a 50% success
rate over time in extremely complex cases if you do it in an appro-
priate way, so it is worth it.rdiovascular Surgery c Volume 148, Number 3 887
